logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

Yum China (09987) spent HK$7.7113 million on March 20 to buy back 18,400 shares.

date
21:08 22/03/2026
avatar
GMT Eight
Panda Retail Company (09987) announced on March 20, 2026 to spend $2,999,980 to repurchase 57,500 shares; and spend HK$7,711,300 to repurchase 18,400 shares.
YUM CHINA (09987) issued an announcement, stating that it will repurchase 57,500 shares for a total of $299.998 million US dollars on March 20, 2026; and repurchase 18,400 shares for a total of $771.13 million Hong Kong dollars.
Related Articles
HK Stock
BASETROPHY GP (08460) will establish a strategic partnership with Hai Dao Hong, focusing on the sales and marketing of products related to Hai Hong Mi.
HK Stock
HANSOH PHARMA (03692): HS-20152 injection fluid has been issued with a drug clinical trial approval notice by the National Medical Products Administration.
HK Stock
Hansoh Pharma (03692): HS-10587 tablets have obtained a drug clinical trial approval notification from the National Medical Products Administration.
BASETROPHY GP (08460) will establish a strategic partnership with Hai Dao Hong, focusing on the sales and marketing of products related to Hai Hong Mi.
HK Stock
HANSOH PHARMA (03692): HS-20152 injection fluid has been issued with a drug clinical trial approval notice by the National Medical Products Administration.
HK Stock
Hansoh Pharma (03692): HS-10587 tablets have obtained a drug clinical trial approval notification from the National Medical Products Administration.
HK Stock
RECOMMEND
State Reform Fund And Three Major Banks Backstop Voyah As It Secures Hong Kong’s First Auto IPO This Year
State Reform Fund And Three Major Banks Backstop Voyah As It Secures Hong Kong’s First Auto IPO This Year
icon
20/03/2026
Hong Kong IPO Irregularities Surface As Corner Placements And Retail Losses Emerge, Haizhi Technology Implicated
Hong Kong IPO Irregularities Surface As Corner Placements And Retail Losses Emerge, Haizhi Technology Implicated
icon
20/03/2026
Gold And Silver Experience Sharp Sell‑Off As Global Rate‑Hike Expectations Intensify
Gold And Silver Experience Sharp Sell‑Off As Global Rate‑Hike Expectations Intensify
icon
20/03/2026
logo
Contact US
qr
+852 - 60190728
[email protected]
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.